Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[umiak]

8/17/2016- Expected upcoming significant milestones +shr structure/OS:

*** Issuance of KIT-302's clinical trial full study report

*** Completion of six-month stability testing of KIT-302

*** Submission to the FDA of the New Drug Application for KIT-302

*** Initiation of a renal function clinical trial to demonstrate the

*** Beneficial effects of KIT-302 on kidney function


ADS equivalents:

Ordinary shares - 6,769,860
Series "A" warrants - 6,835,669
Series 6/14 options - 4,572.75
Series 7/14 options - 2,307.6
Series 5/15 options - 2,239.3
Series 9/15 options - 86,000
Underwriter warrants - 157,945
Emp. Incentive options - 364,068
Pre-funded warrants - 865,000 (not tradable)
Agent warrants - 141,176

Fully diluted = 15,228,838 assuming everything is exercised